Meeting
2021 ASCO Annual Meeting
Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).
Authors
Karie Runcie
Columbia University Medical Center, New York, NY
Karie Runcie , Eric A. Singer , Moshe Chaim Ornstein , Christopher B. Anderson , Matthew Dallos , Jessica Hawley , Emerson A. Lim , Charles G. Drake , Benjamin Izar , Hiram A. Shaish , Mark N. Stein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT04322955
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4598)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4598
Abstract #
TPS4598
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK).
First Author: Karie Runcie
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial.
First Author: Karie Runcie
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani